Quantcast

Latest Roswell Park Cancer Institute Stories

2009-11-23 13:03:00

Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL). FORT WASHINGTON, Pa., Nov. 23 /PRNewswire-USNewswire/ -- Two recent FDA approvals have prompted the...

2009-11-20 10:39:00

NCCN program on Discovery Health Channel profiles patients undergoing treatment for metastatic breast cancer and their physicians' use of the NCCN Clinical Practice Guidelines in Oncology(TM) for Breast Cancer to determine an individualized treatment regimen. The program, which provides free CME credits, premieres on Sunday, November 22 at 7:00 am EST. FORT WASHINGTON, Pa., Nov. 20 /PRNewswire-USNewswire/ -- Although October (National Breast Cancer Awareness Month) is behind us, it...

2009-11-10 08:12:00

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, Pa., Nov. 10 /PRNewswire-USNewswire/ -- The National Comprehensive...

2009-11-03 09:44:00

The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines. FORT WASHINGTON, Pa., Nov. 3 /PRNewswire-USNewswire/ -- Following the...

2009-11-02 10:13:00

Although colonoscopy remains the preferred colorectal cancer screening method, the recently updated NCCN Guidelines for Colorectal Cancer Screening have added annual immunohistochemical stool testing with or without a flexible sigmoidoscopy every five years as an alternate screening option for average risk individuals. Additional updates include guidelines for individuals with three rare syndromes putting them at greater risk for developing the disease. FORT WASHINGTON, Pa., Nov. 2...

2009-10-26 16:04:00

SEATTLE, Oct. 26 /PRNewswire/ -- Building on the strengths of two institutions separated by nearly 9,000 miles over two continents - both renowned in their work in the fight against cancer - the United States Agency for International Development has awarded a $500,000 grant to Fred Hutchinson Cancer Research Center to aid in the construction of the first American cancer clinic and medical-training facility in Africa. "This is the first true collaboration between an African and a U.S....

2009-10-19 07:31:00

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Acute Myeloid Leukemia (AML), the most common acute leukemia affecting adults. Noteworthy updates include the incorporation of risk stratification based on white blood cell count, the alternative to use cord blood in allogeneic stem cell transplants, and new treatment options for adults over the age of 60 with AML FORT WASHINGTON, Pa., Oct. 19 /PRNewswire-USNewswire/ -- The National Comprehensive...

2009-10-15 08:02:00

NCCN has added pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA-approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009 FORT WASHINGTON, Pa., Oct. 15 /PRNewswire-USNewswire/ -- Upon the recent FDA approval of pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) for the treatment of...

2009-10-01 07:00:00

CHICAGO, Oct. 1 /PRNewswire/ -- According to new research from the American College of Surgeons (ACoS), two-thirds of women (66 percent) did not know about accreditation of breast care centers, what it means, and why it is important. However, after providing women who were surveyed with an overview of the meaning of accreditation, they overwhelmingly (92 percent) find it to be an important aspect in choosing a breast cancer treatment facility. To be "accredited," breast care centers...

2009-09-14 07:00:00

NCCN is holding the NCCN Oncology Research Best Practices Conference(TM), an interactive forum to discuss the regulatory and operational aspects of research and help identify areas in the clinical trial process where improvements can be made. Scheduled for October 26 - 27 in Bethesda, MD, the conference will include lectures, interactive workshops, and panel discussions on topics that challenge the conduct of oncology research as well as topics related to ethical considerations. FORT...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.